ArticleFrontiers in oncology2026
Predictive value of IGF2BP2 for endometrial cancer recurrence: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Predictive value of IGF2BP2 in combination with clinicopathological parameters for postoperative recurrence in endometrial cancer (EC): development and validation of a prognostic model. Methods: This multicenter study retrospectively enrolled patients with endometrial cancer who underwent standard surgical treatment between January 2016 and January 2023. The cohort included 545 patients from the First Affiliated Hospital of Chongqing Medical University (training set) and 315 patients from two independent centers-Liangjiang Hospital of Chongqing Medical University and Women and Children's Hospital of Chongqing Medical University (validation set). Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors associated with recurrence-free survival (RFS), followed by the development of a nomogram-based prediction model. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC), and calibration curves were used to assess the agreement between predicted and observed outcomes. Risk stratification was performed according to nomogram-derived scores, and the clinical applicability of the model was further validated through Kaplan-Meier survival analysis. Results: Multivariate Cox regression analysis identified International Federation of Gynecology and Obstetrics(FIGO) stage (p=0.001), depth of myometrial invasion (p=0.004), histologic type (p=0.001), CA125 level (p=0.001), p53 status (p=0.013), lymphovascular space invasion (p=0.007), and IGF2BP2 expression (p<0.001) as independent prognostic factors for RFS in endometrial cancer patients. The integrated prediction model incorporating these factors demonstrated excellent performance in predicting 1-, 3-, and 5-year RFS, with significantly superior discriminative ability (AUC = 0.884) compared to single-parameter models. Conclusion: The nomogram integrating IGF2BP2 with clinicopathological parameters demonstrates robust accuracy for predicting recurrence-free survival in endometrial cancer patients. This tool provides a quantitative risk stratification framework that could potentially contribute to prognostic assessment, though its clinical implementation awaits validation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.